Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


“Comprehensive” Drug Shortage Mitigation Bill Under Development In House

Executive Summary

Like the Senate proposal, it could include reimbursement rate adjustments in addition to requiring early notification of shortages by manufacturers, but questions remain about ensuring there are no unintended consequences.


Related Content

Drug Shortage Bill In House Refines Hatch Reimbursement Proposal
Drug Shortages Proposal From Sen. Hatch Offers 7-Year Economic Incentives
FDA’s Drug Shortage Reg Adds More Manufacturers, Products To Notification List
FDA’s Drug Shortage Prevention Tally: 96 Saves In Six Weeks
Medicare Reimbursement Rate Targeted As Culprit For Drug Shortages
Drug Shortage Fixes Migrating Toward Economics
Obama's Drug Shortage Efforts Focus On Personnel, Persuasion
FDA's Drug Shortages Strategy Focuses On Prevention, Not "Empire Building"
Drug Shortages: Can The Blame Game Help Find Solutions?
To Prevent Drug Shortages, Don't Look To Inspections, FDA Says





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts